Cherry Ma focuses her practice on corporate finance and capital markets. Cherry advises clients on Hong Kong initial public offerings, mergers and acquisitions, regulatory compliance, and general corporate matters.
- CICC, CCB, CMB, CMS and other underwriters in the approximately US$150 million IPO of Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) on the Hong Kong Stock Exchange
- Sipai Health Technology Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
- 3D Medicines Inc. in its US$52 million IPO and listing on the Hong Kong Stock Exchange
- China VAST Industrial Urban Development (6166.HK) and its controlling shareholder, Profit East Limited, in the US$285 million all-cash take private proposal by China Jinmao Holdings Group Limited (817.HK)
Languages
- English
- Cantonese
- Mandarin
Admissions
- Hong Kong
Education
- The Chinese University of Hong Kong, P.C.L.L.
- The Chinese University of Hong Kong, J.D.; B.A.
Related Practices